<DOC>
	<DOCNO>NCT01519323</DOCNO>
	<brief_summary>This open-label , multicenter . single arm Phase I dose-escalation study efficacy tail extension evaluate maximum tolerate dose/recommended dose , safety efficacy vemurafenib ( RO5185426 ) pediatric participant ( age 12 17 ) newly diagnose recurrent surgically incurable unresectable Stage IIIC Stage IV melanoma harbor BRAFV600 mutation . Participants receive vemurafenib orally twice daily disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>BRIM-P : A Study Vemurafenib Pediatric Patients With Stage IIIC Stage IV Melanoma Harboring BRAFV600 Mutations</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Pediatric participant , 12 17 year age inclusive Histologically confirm surgically incurable unresectable Stage IIIC Stage IV ( AJCC ) melanoma Positive protooncogene BRaf ( BRAF ) mutation result ( Cobas 4800 BRAF V600 Mutation Test ) Measurable disease accord Response Evaluation Criteria In Solid Tumors ( RECIST ) criteria Performance status : Karnofsky ( participant &gt; /= 16 year age ) Lansky ( participant &lt; 16 year age ) score &gt; /= 60 Adequate bone marrow , liver renal function Participants must fully recover acute toxic effect prior therapy prior first administration study drug Active untreated central nervous system ( CNS ) lesions History know spinal cord compression carcinomatous meningitis Anticipated ongoing administration anticancer therapy administer study Previous malignancy within past 5 year except basal squamous cell carcinoma skin , melanoma insitu , carcinoma insitu cervix Previous treatment selective/specific BRAF Methyl Ethyl Ketone ( MEK ) inhibitor ( previous treatment sorafenib allow ) Any previous treatment study drug ( RO5185426 ) participation clinical trial include RO5185426 Pregnant lactate female Known human immunodeficiency virus ( HIV ) positivity acquire immune deficiency syndrome ( AIDS ) relate illness , active hepatitis B virus , active hepatitis C virus</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>